Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU) SAR/SUSAR Mette Krag Dept. of Intensive Care 4131 Copenhagen University Hospital Rigshospitalet,

Slides:

Advertisements

Similar presentations

Susan Burner Bankowski, M.S., J.D. Chair, OHSU IRB

Advertisements

Safety Reporting IN Clinical Trials

ADVERSE EVENT REPORTING

Chicken Soup for the Busy Coordinator Aug Scenario: Aim: Randomised, double-blind, phase III clinical trial to compare the safety and efficacy of.

Pharmacovigilance Dr. Muiris Dowling,

Adverse Event Reporting. Reporting Adverse Events Adverse Events (AEs) are “... any untoward medical occurrence in a subject that was not previously identified.

{ ADVERSE DRUG REACTIONS To ensure patient, family/caregiver and home health personnel are instructed to identify adverse reactions to medications and.

Elements of a clinical trial research protocol

Update: 21 CFR PART 312 FDA Safety Reporting Requirements for INDs

Capturing and Reporting Adverse Events in Clinical Research

Pharmacovigilance Lindsey Connery Pharmacovigilance Manager, Cancer Research UK Clinical Trials Unit, Glasgow.

Fulfilling the Promise of Medicine Together New FDA Safety Reporting Requirements 2010 John McLane, Ph.D. COO & Vice President Clinical and Regulatory.

FDA MedWatch and Patient Safety. Dietary Supplement and Nonprescription Drug Consumer Protection Act of 2006  The Act defines a ‘serious adverse event’

SAE Report CTT21 V To:Quality Assurance Research & Development 34 Hyde Terrace LS2 9LN Date:…………………………….. Fax To:+44(0) From (name):………………………..

Requirements of EU pharmacovigilance legislation for distributors Julia Sipos Quality Management Director Pharmacovigilance coordinator Version 03.

Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?

SERIOUS ADVERSE EVENTS REPORTING Elizabeth Dayag IRB Administrator Naval Medical Center Portsmouth.

Template for study specific training for Intrapartum Research Studies [ Please see guide before using this]

Adverse Events and Unanticipated Problems Presented by: Karen Jeans, PhD, CCRN, CIP COACH Program Analyst.

Paula Peyrani, MD Division of Infectious Diseases University of Louisville Performing the Study.

1 Nuts and Bolts of Safety Reporting The Role of the CRO Dr. Noa Lowenton Spier Pharma-Clinical S.A.G.

Adverse Event Reporting.

Development and Approval of Drugs and Devices EPI260 Lecture 9 May 23, 2012 Richard Chin, M.D.

H. Lundbeck A/S21-Sep-151 Pharmacovigilance during clinical development SAE reporting, ASUR and PSUR IFF Seminar, 21. February 2007.

SAE Reporting Judy Breed, BA, RN June, 2011 CONFIDENTIAL.

Collecting data in clinic.  Aim of BADBIR  Definition of Adverse Events  Adverse events in BADBIR  Adverse event recording in hospital case notes.

ADVERSE EFFECTS OF DRUGS Phase II May Adverse Drug Reaction An adverse reaction to a drug is a harmful or unintended response. ADRs are claimed.

AE/SAE/EAE Identification and Reporting AE/SAE/EAE Identification and Reporting.

Reporting Scenario # 2 September 18, Scenario # 2 Mr. Hall, 62 yr old man with acute MI, is to receive autologous mobilized PBSCs delivered via.

METHODS TO STUDY DRUG SAFETY PROBLEMS animal experiments clinical trials epidemiological methods –spontaneous reporting case reports case series –Post-Marketing.

The SToP-BPD study Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants Initiation visit.

EAE Training EAE Reporting and Assessment Overview DAIDS Regional Training Event, Regulatory Compliance Center Kampala, Uganda, September 2009 DAIDS Regional.

Smallpox Vaccine Safety and Reporting Adverse Events Department of Health and Human Services Centers for Disease Control and Prevention December 2002.

Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU) Screening and randomisation Mette Krag Dept. of Intensive Care 4131 Copenhagen University.

Mette Krag, MD, coordinating investigator

Copenhagen University Hospital Rigshospitalet, Denmark

Serious Adverse Event Reporting Start-up Meeting March 25, 2010 Kingston, ON.

European Patients’ Academy on Therapeutic Innovation Introduction to pharmacovigilance Monitoring the safety of medicines.

Role of Site Investigator Ensure subject safety is protected & well-managed Full compliance with requirements of Good Clinical Practice (GCP) Conduct the.

D3 ) Not Recovered d5) Fatal Was a post-mortem undertaken?YesNo Was the SAE ongoing at time of death from other cause? Yes No d d m m y y y y d1) Recovered.

REPORTING ADVERSE EVENTS AND COMPLETING THE REPORT FORM

Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP

Søren Marker Jensen, MD, coordinating investigator

Reportable Events Emory IRB 9/11/2014.

Safety Reporting V6.0 17/01/17.

Assessing expectedness of an adverse event

Copenhagen University Hospital Rigshospitalet, Denmark

Copenhagen University Hospital Rigshospitalet, Denmark

Administering Informed Consent Issues for Discussion

Safety Reporting Nichol McBee, MPH, CCRP.

Expedited Adverse Event Reporting Requirements

Remote Monitoring of Adverse Events

Copenhagen University Hospital Rigshospitalet, Denmark

3. Key definitions Multi-partner training package on active TB drug safety monitoring and management (aDSM) July 2016.

Pharmacovigilance in clinical trials

Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP

Expedited Adverse Event Reporting Requirements

*Continue on SAE supplemental page CTT21 A if more space is required

Remote Monitoring of Adverse Events

SERIOUS ADVERSE EVENTS REPORTING

Copenhagen University Hospital Rigshospitalet, Denmark

Copenhagen University Hospital Rigshospitalet, Denmark

WHAT TO DO IF A PATIENT DEVELOPS AN UNEXPECTED PROBLEM?

Ramy Abdelrahman, MD Division of Pediatric and Maternal Health (DPMH)

Copenhagen University Hospital Rigshospitalet, Denmark

Søren Marker Jensen Dept. of Intensive Care 4131

Dr Tim England TICH-2 SAE adjudicator

Copenhagen University Hospital Rigshospitalet, Denmark

Copenhagen University Hospital Rigshospitalet, Denmark

Serious Adverse Event Reconciliation

Presentation transcript:

Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU) SAR/SUSAR Mette Krag Dept. of Intensive Care 4131 Copenhagen University Hospital Rigshospitalet, Denmark SUP-ICU

Definitions, AR and SAR Adverse reaction (AR): any undesirable and unintended medical response related to the intervention occurring to a patient during a clinical trial. Adverse reactions are specified in the product characteristics of pantoprazole Serious adverse reaction (SAR): any adverse reaction (as defined above) that results in death, is life- threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity SUP-ICU

Definitions, AE and SAE Adverse event (AE): any undesirable medical event occurring to a patient during a clinical trial, which does not necessarily have a causal relationship with the intervention Serious adverse event (SAE): any adverse event that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity SAEs will not be recorded as an entity, because the majority of ICU patients will experience several SAEs during their critical illness. The most important SAEs will be captured in the secondary outcome measures (days alive without life-support). Patient charts, notes and lab reports will contain daily registrations of clinical data, which can be obtained on request from the medical authorities. SUP-ICU

SARs i SUP-ICU SARs are ALWAYS related to the trial medication. SARs in SUP-ICU are defined in the protocol appendix 4. The following conditions are considered SARs when related to the intervention: Anaphylactic reactions Agranulocytosis Pancytopenia Acute hepatic failure Steven-Johnson syndrome and toxic epidermal necrolysis Interstitial nephritis Angioedema (Quincke’s oedema) SUP-ICU

SUSAR Suspected Unexpected Serious Adverse Reaction Any suspected adverse reaction which is both serious and unexpected. SUSARs will be defined as serious reactions not described in the summaries of product characteristics for pantoprazole. SUP-ICU

SAR/SUSAR SARs and SUSARs (not SAEs) have to be reported within 24 hours Phone: (available 24/7) Please complete the SAR/SUSAR form: → ‘trial documents’ SUP-ICU

SUSAR Trial investigators are to report SUSARs without any delay to the sponsor, which in turn will report these to the Danish Health and Medicine Authorities 7 days at the latest after the report has been received SUP-ICU

Unblinding If an adverse reaction is considered to be a SAR or a SUSAR you may need to unblind the trial medication If the situation allows it please always call the coordinating centre before unblinding the trial medication Unblinding: 1.Pulling of the blinding label (only if the situation requires immediate unblinding) Active drug: original label of pantoprazole will be visible at the vial after removing the blinding label Placebo: Empty label at the vial after removing the blinding label 2.Contact the coordinating centre by OR call the SUP-ICU hotline Please refer to the identifier number at the vial (to be found in the medication distribution system). SUP-ICU